ArticleEULAR rheumatology open2025
The temporal mortality trend in seropositive and seronegative rheumatoid arthritis: a Danish population-based cohort study.
Article in EULAR rheumatology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study investigated the 5-year all-cause mortality trend for women and men with seropositive versus seronegative rheumatoid arthritis (RA) compared with the background population (BP). Methods: Using nationwide registers, a population-based cohort of incident patients with RA diagnosed in Denmark between 2000 and 2014 was identified. Based on immunoglobulin M-rheumatoid factor and/or anticitrullinated peptides, a prespecified algorithm was used to determine the serologic status. The pseudo-observation method was used to determine the cumulative incidence proportion, the age-adjusted risk difference, and the relative risk of mortality. Results: During the study period, the cumulative incidence proportion decreased by at least 50% for both the BP and the RA cohort. The largest change in relative risk was seen for men with seropositive RA compared with seronegative RA, with a relative risk 2000-2004 of 1.1 (95% CI, 0.9-1.4) to a relative risk of 1.4 (95% CI, 1.2-1.7) in 2010-2014. No significant difference was observed for women stratified by serology. Patients with seropositive RA continued to have an excess mortality risk compared with the BP, whereas the relative risk for patients with seronegative RA became similar to the BP. Conclusions: A higher 5-year all-cause mortality risk persisted for patients with seropositive RA compared with the BP. Men with seropositive RA had a higher mortality risk than men with seronegative RA, a difference not seen in women. Future studies are needed to explore the findings of higher mortality risk in seropositive patients and especially the influence of sex and confounders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.